Navigation Links
Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
Date:1/9/2014

icant step forward in the management of early breast cancer.

AVB-620, a fluorescent peptide, delivers a real-time intraoperative cancer diagnosis in the form of a luminous map, providing surgeons with enough information to make a decision during the first surgery as opposed to waiting for the results of limited pathology reports. In preclinical testing, the in vivo accuracy of AVB-620 is >95%.

"AVB-620 will enable surgeons to identify cancerous tissue during the surgical procedure, addressing a key unmet need in the oncologic surgery space," said Carmine Stengone, CEO of Avelas. "This capability will allow surgeons to make real-time decisions that will improve patient treatment and lead to significant cost savings by reducing surgical time and the number of re-operations."

The ACI technology, founded by Nobel Prize winning scientist Roger Tsien, Ph.D., utilizes the increased activity of enzymes called proteases that occur in tumors and metastases. The fluorescent peptide illuminates in the presence of pathological protease activity, thereby marking the cancerous tissue. When used in conjunction with a fluorescence imaging camera system during surgery, a color-coded image showing cancerous tissue is superimposed onto the normal surgical view, providing the surgeon a map of the cancer location.

About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing fluorescent technologies that advance a new standard-of-care for cancer surgery. Its lead candidate, AVB-620, is expected to enter clinical studies in 2014. Avelas was founded by Avalon Ventures on technology from Nobel Prize winner Roger Tsien, Ph.D.  For additional information, please visit www.avelasbio.com.


'/>"/>
SOURCE Avelas Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
2. Sangamo BioSciences Announces Conference Call And Webcast To Discuss Global Collaboration with Biogen Idec to Develop Treatments for Hemoglobinopathies
3. Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
4. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
5. Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
6. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
8. Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
9. Proove Biosciences CEO Brian Meshkin Wins 2013 Bridging the Gap Award by the Greater Baltimore Committee
10. Sangamo BioSciences Announces Presentation At The 25th Annual Piper Jaffray Healthcare Conference
11. Telomere Biosciences Announces: TELO-100 with T-Activator 150, a Breakthrough in Telomere Science and Age Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is ... been elected Chairman of the Board, to succeed Donald ... CEO, but will continue as a member of the Board.  ... has added to the company over almost twenty years, the ... The Board of Directors has established a Search Committee to ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
(Date:12/17/2014)... Achim Noack has been named global vice president ... position, Noack will assist Jerry Stoller, CEO and president ... and supervise global marketing management and implementation of new ... and experience in the crop protection industry,” says Jerry ... thinking will be a great asset for Stoller Group, ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" ... high-quality,pharmaceutical grade glucose products in China, today announced ... months ended September 30, 2008,after the close of ... will conduct a conference call on Friday, November ...
... class drug illustrates early signal of transport of ... Exchange Symbol: RVX CALGARY, Nov. 10 /PRNewswire-FirstCall/ ... with its lead drug,RVX-208, a first in class ... Phase 1a clinical trial found that treatment with ...
... Overall Survival, Summary: Three ofatumumab Abstracts Have Been Accepted for ... ... Genmab A/S (OMX: GEN),announced today that three ofatumumab (HuMax-CD20(R)) ... of Hematology Annual,Meeting and Exposition (ASH) December 6-9, 2008. Updated ...
Cached Biology Technology:Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 2Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 3RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 2RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 3RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 4Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH 2Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH 3
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... By studying mice with skin cancer, researchers at the Huntsman ... to inhibit a mutant gene found in up to 30 ... this gene are important in cell signaling, or communication among ... gene that has been shown to promote the growth of ...
... when and where certain proteins are made is crucial ... proteins, information from DNA is transcribed into RNA molecules ... of proteins. But not all genes code for proteins--some ... interfere with--and therefore control--the production of proteins. A new ...
... partially differentiated stem cells with gene therapy can promote the ... spinal cords of rats, a new study shows. The treatment, ... improves the animals' motor function and electrical conduction from the ... to new ways of treating spinal cord injury in humans. ...
Cached Biology News:Scientists inhibit cancer gene 2MicroRNAs play a big part in gene regulation - and evolution 2Combination therapy leads to partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in rats 3
... Processing mini Tray (3 per pack), ... staining and blot processing.Automated staining of ... proteins and nucleic acid analysis.Prepares blots ... chromogenic detection.Programmable control of protocol, solution, ...
... 1 g. High quality kits ... preparation that give consistent and ... and tissues.Clean up samples from ... Accurately quantitate protein for first-dimension ...
GOAT ANTI CARICA PAPAYA PAPAIN...
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
Biology Products: